Tscan therapeutics presents initial phase 1 clinical results on tsc-100 and tsc-101 at the 65th american society of hematology annual meeting and exposition

No relapses have occurred in six of six treatment-arm patients, four with follow-up past six months; one of four control-arm patients relapsed at six months and two others required clinical intervention

TCRX Ratings Summary

TCRX Quant Ranking